Active Biotech
Active Biotech reports study results with tasquinimod in heavily pre-treated patients with relapsed refractory multiple myeloma
Lund, May 23, 2025 – Active Biotech (NASDAQ Stockholm; ACTI) announced today study results of tasquinimod in combination with ixazomib (proteasome inhibitor, PI), lenalidomide (Imid) and dexamethasone (IRd) in heavily pre-treated patients with relapsed refractory multiple myeloma. The results confirm that tasquinimod has anti-myeloma activity and is well tolerated in patients previously refractory to Imid/PI combination therapy. The results will be presented as a poster at the American Society of Clinical Oncology (ASCO) annual meeting on June 1, 2025.
“These results confirm the feasibility of combining tasquinimod in an all-oral combination with standard-of-care agents for patients with multiple myeloma who have exhausted other treatment options,” said Dr. Dan Vogl, Principal Investigator.
In this analysis, a total of 17 patients received tasquinimod in combination with IRd. During dose-escalation, no dose-limiting toxicities were observed, and dose level two (tasquinimod 1 mg daily after a one week run-in at 0.5 mg daily) was selected as the dose for the expansion cohort.
Patients were heavily pretreated with a median of 7 prior lines of therapy (range 4-19) and all were triple-class refractory with 71% (12 pts) refractory to their most recent Imid/PI combination. Among these 12 patients, there was one durable Partial Response (PR) and three Minimal Responses (MR). These data are in line with previously reported results confirming the safety, tolerability and anti-myeloma effect of tasquinimod alone and in combination with IRd in patients with relapsed refractory multiple myeloma.
”Importantly, the observed responses in patients with myeloma previously refractory to an Imid/PI combination, who would not be expected to respond to the IRd backbone regimen, suggest synergistic efficacy of tasquinimod with IRd. These results highlight the potential for targeting the tumor microenvironment as a way to augment the efficacy of other myeloma therapies,” said Dr. Vogl.
The study (NCT04405167), which is conducted at Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, has closed to enrolment, and the full study results are being analyzed.
The abstract is available online on https://meetings.asco.org/ after 5 PM (ET) on May 22.
Details on the presentation:
Abstract Title: Clinical Activity of Novel Targeting of S100A9 with Tasquinimod for Relapsed and Refractory Multiple Myeloma (RRMM)
Session Title: Hematologic Malignancies – Plasma Cell Dyscrasia
Abstract Number: 7555
Session Date and Time: June 1, 2025, 8:00 AM-12:00 AM (ET)
Datum | 2025-05-23, kl 08:30 |
Källa | MFN |
